Skip to main content
SpringerLink
Log in

Controversies in the Treatment of Women with Early-Stage Epithelial Ovarian Cancer

  • Chapter
  • First Online:
Controversies in the Management of Gynecological Cancers

  • 1066 Accesses

Abstract

The management of women with apparent early-stage epithelial ovarian cancer presents a wide range of interlinked diagnostic and therapeutic challenges and controversies including surgical staging and surgical and medical treatments. We provide a critical overview of the most debated and controversial aspects of this challenging disease. In surgery, we focus on confidence in initial staging and the impact of under-assessment and undertreatment, the appropriate degree of surgical radicality, and need for lymphadenectomy, as well as the importance of fertility preservation in women with very early disease. We review the evidence for the need for adjuvant therapies and the optimum regimens particularly addressing the impact on younger women and long-term treatment sequelae in survivors.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Collins GS, Altman DG. Identifying women with undetected ovarian cancer: independent and external validation of QCancer(®) (Ovarian) prediction model. Eur J Cancer Care (Engl). 2013;22(4):423–9.

    Article  CAS  Google Scholar 

  2. Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol. 2000;19:3–10.

    Article  CAS  PubMed  Google Scholar 

  3. Oncology FCoG. Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia. Int J Gynaecol Obstet. 2009;105:3–4.

    Article  Google Scholar 

  4. Young RC, Walton LA, Ellenberg SS, et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med. 1990;322:1021–7.

    Article  CAS  PubMed  Google Scholar 

  5. Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet. 2006;95 Suppl 1:S161–92.

    Article  PubMed  Google Scholar 

  6. Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248–59.

    Article  PubMed  Google Scholar 

  7. Wright JD, Lewin SN, Deutsch I, et al. Defining the limits of radical cytoreductive surgery for ovarian cancer. Gynecol Oncol. 2011;123(3):467–73.

    Article  PubMed  Google Scholar 

  8. SEER_faststats. Stage Distribution (SEER summary stage 2000) for ovarian cancer, all ages, all races, female: 2000–2008. http://seer.cancer.gov/statfacts/html/ovary.html

  9. Braicu EI, Sehouli J, Richter R, et al. Role of histological type on surgical outcome and survival following radical primary tumour debulking of epithelial ovarian, fallopian tube and peritoneal cancers. Br J Cancer. 2011;105(12):1818–24.

    Article  PubMed Central  PubMed  Google Scholar 

  10. Vergote I, Amant F. Time to include high-risk early ovarian cancer in randomized phase III trials of advanced ovarian cancer. Gynecol Oncol. 2006;102:415–7.

    Article  PubMed  Google Scholar 

  11. du Bois A, Herrstedt J, Hardy-Bessard AC, et al. Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. J Clin Oncol. 2010;28(27):4162–9. doi:10.1200/JCO.2009.27.4696. Epub 2010 Aug 23.

  12. Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009;374:1331–8.

    Article  CAS  PubMed  Google Scholar 

  13. du Bois A, Herrstedt J, Hardy-Bessard AC, Müller HH, Harter P, Kristensen G, Joly F, Huober J, Avall-Lundqvist E, Weber B, Kurzeder C, Jelic S, Pujade-Lauraine E, Burges A, Pfisterer J, Gropp M, Staehle A, Wimberger P, Jackisch C, Sehouli J. Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. J Clin Oncol. 2010 Sep 20;28(27):4162-9. doi:10.1200/JCO.2009.27.4696. Epub 2010 Aug 23.

  14. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM, ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484–96.

    Article  CAS  PubMed  Google Scholar 

  15. Menon U, Gentry-Maharaj A, Hallett R, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009;10:327–40.

    Article  PubMed  Google Scholar 

  16. Bristow RE, Smith A, Zhang Z, et al. Ovarian malignancy risk stratification of the adnexal mass using a multivariate index assay. Gynecol Oncol. 2013;128(2):252–9.

    Article  PubMed  Google Scholar 

  17. Dizon DS, Restivo A, Lomme M, et al. For women receiving chemotherapy for clinically apparent early ovarian cancer, is there a benefit to surgical staging? Am J Clin Oncol. 2008;31(1):39–42.

    Article  PubMed  Google Scholar 

  18. Timmers PJ, Zwinderman AH, Coens C, et al. Understanding the problem of inadequately staging early ovarian cancer. Eur J Cancer. 2010;46(5):880–4.

    Article  CAS  PubMed  Google Scholar 

  19. Kumar Dhingra V, Kand P, et al. Impact of FDG-PET and -PET/CT imaging in the clinical decision-making of ovarian carcinoma: an evidence-based approach. Womens Health (Lond Engl). 2012;8(2):191–203.

    Article  Google Scholar 

  20. Garcia-Soto AE, Boren T, Wingo SN, Heffernen T, Miller DS. Is comprehensive surgical staging needed for thorough evaluation of early-stage ovarian carcinoma? Am J Obstet Gynecol. 2012;206(3):242.e1–5.

    Google Scholar 

  21. Shroff R, Brooks RA, Zighelboim I, et al. The utility of peritoneal biopsy and omentectomy in the upstaging of apparent early ovarian cancer. Int J Gynecol Cancer. 2011;21(7):1208–12.

    PubMed  Google Scholar 

  22. Trimbos JB, Vergote I, Bolis G, Vermorken JB, Mangioni C, Madronal C, et al., EORTC-ACTION collaborators. European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst. 2003;95(2):113–25.

    Google Scholar 

  23. Chang SJ, Bristow RE, Ryu HS. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer. Ann Surg Oncol. 2012;19(13):4059–67.

    Article  PubMed  Google Scholar 

  24. Chang SJ, Bristow RE. Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: redefining ‘optimal’ residual disease. Gynecol Oncol. 2012;125(2):483–92.

    Article  PubMed  Google Scholar 

  25. http://www.cancer.org/cancer/ovariancancer/detailedguide/ovarian-cancer-staging.

  26. Le T, Adolph A, Krepart GV, et al. The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma. Gynecol Oncol. 2002;85:351–5.

    Article  PubMed  Google Scholar 

  27. Powless CA, Bakkum-Gamez JN, Aletti GD, et al. Random peritoneal biopsies have limited value in staging of apparent early stage epithelial ovarian cancer after thorough exploration. Gynecol Oncol. 2009;115(1):86–9.

    Article  PubMed  Google Scholar 

  28. Benedetti-Panici P, Greggi S, Maneschi F, et al. Anatomical and pathological study of retroperitoneal nodes in epithelial ovarian cancer. Gynecol Oncol. 1993;51(2):150–4.

    Article  CAS  PubMed  Google Scholar 

  29. Petru E, Lahousen M, Tamussino K, et al. Lymphadenectomy in stage I ovarian cancer. Am J Obstet Gynecol. 1994;170(2):656–62.

    Article  CAS  PubMed  Google Scholar 

  30. Onda T, Yoshikawa H, Yokota H, et al. Assessment of metastases to aortic and pelvic lymph nodes in epithelial ovarian carcinoma. A proposal for essential sites for lymph node biopsy. Cancer. 1996;78(4):803–8.

    Article  CAS  PubMed  Google Scholar 

  31. Baiocchi G, Grosso G, di Re E, et al. Systematic pelvic and paraaortic lymphadenectomy at second-look laparotomy for ovarian cancer. Gynecol Oncol. 1998;69(2):151–6.

    Article  CAS  PubMed  Google Scholar 

  32. Suzuki M, Ohwada M, Yamada T, et al. Lymph node metastasis in stage I epithelial ovarian cancer. Gynecol Oncol. 2000;79(2):305–8.

    Article  CAS  PubMed  Google Scholar 

  33. Nomura H, Tsuda H, Susumu N, et al. Lymph node metastasis in grossly apparent stages I and II epithelial ovarian cancer. Int J Gynecol Cancer. 2010;20(3):341–5.

    Article  PubMed  Google Scholar 

  34. Maggioni A, Benedetti Panici P, Dell’Anna T, et al. Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis. Br J Cancer. 2006;95(6):699–704.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  35. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000582/human_med_000663.jsp&mid=WC0b01ac058001d124.

  36. Musumeci R, Banfi A, Bolis G, et al. Lymphangiography in patients with ovarian epithelial cancer. Cancer. 1977;40:1444–9.

    Article  CAS  PubMed  Google Scholar 

  37. Burghadt E, Girardi F, Lahousen M, et al. Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer. Gynecol Oncol. 1991;40:103–6.

    Article  Google Scholar 

  38. Rungruang B, Miller A, Richard SD, et al. Should stage IIIC ovarian cancer be further stratified by intraperitoneal vs. retroperitoneal only disease?: a Gynecologic Oncology Group study. Gynecol Oncol. 2012;124(1):53–8. doi:10.1016/j.ygyno.2011.09.024.

    Article  PubMed  Google Scholar 

  39. Ditto A, Martinelli F, Reato C, et al. Systematic para-aortic and pelvic lymphadenectomy in early stage epithelial ovarian cancer: a prospective study. Ann Surg Oncol. 2012;19(12):3849–55. doi:10.1245/s10434-012-2439-7.

    Article  PubMed  Google Scholar 

  40. Schmeler KM, Tao X, Frumovitz M, et al. Prevalence of lymph node metastasis in primary mucinous carcinoma of the ovary. Obstet Gynecol. 2010;116:269–73.

    Article  PubMed  Google Scholar 

  41. Kleppe M, Wang T, Van Gorp T, et al. Lymph node metastasis in stages I and II ovarian cancer: a review. Gynecol Oncol. 2011;123(3):610–4.

    Article  CAS  PubMed  Google Scholar 

  42. Powless CA, Aletti GD, Bakkum-Gamez JN, et al. Risk factors for lymph node metastasis in apparent early-stage epithelial ovarian cancer: implications for surgical staging. Gynecol Oncol. 2011;122(3):536–40.

    Article  PubMed  Google Scholar 

  43. Harter P, Gnauert K, Hils R, et al. Pattern and clinical predictors of lymph node metastases in epithelial ovarian cancer. Int J Gynecol Cancer. 2007;17(6):1238–44.

    Article  CAS  PubMed  Google Scholar 

  44. Aletti GD, Dowdy SC, Gostout BS, et al. Quality improvement in the surgical approach to advanced ovarian cancer: the Mayo Clinic experience. J Am Coll Surg. 2009;208(4):614–20.

    Article  PubMed  Google Scholar 

  45. Chi DS, Franklin CC, Levine DA, et al. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol Oncol. 2004;94(3):650–4.

    Article  PubMed  Google Scholar 

  46. Schaafsma BE, van der Vorst JR, Gaarenstroom KN, et al. Randomized comparison of near-infrared fluorescence lymphatic tracers for sentinel lymph node mapping of cervical cancer. Gynecol Oncol. 2012;127(1):126–30. doi:10.1016/j.ygyno.2012.07.002.

    Article  PubMed Central  PubMed  Google Scholar 

  47. Fotopoulou C, Braicu I, Sehouli J. Fertility-sparing surgery in early epithelial ovarian cancer: a viable option? Obstet Gynecol Int. 2012;2012:238061. doi:10.1155/2012/238061.

    PubMed Central  PubMed  Google Scholar 

  48. Satoh T, Hatae M, Watanabe Y, et al. Outcomes of fertility-sparing surgery for stage I epithelial ovarian cancer: a proposal for patient selection. J Clin Oncol. 2010;28(10):1727–32.

    Article  PubMed  Google Scholar 

  49. Zanetta G, Chiari S, Rota S, et al. Conservative surgery for stage I ovarian carcinoma in women of childbearing age. Br J Obstet Gynaecol. 1997;104(9):1030–5.

    Article  CAS  PubMed  Google Scholar 

  50. Kajiyama H, Shibata K, Mizuno M, et al. Fertility-sparing surgery in young women with mucinous adenocarcinoma of the ovary. Gynecol Oncol. 2011;122(2):334–8.

    Article  PubMed  Google Scholar 

  51. Kwon YS, Hahn HS, Kim TJ, et al. Fertility preservation in women with early epithelial ovarian cancer. J Gynecol Oncol. 2009;20(1):44–7. doi:10.3802/jgo.2009.20.1.44.

    Article  PubMed Central  PubMed  Google Scholar 

  52. Borgfeldt C, Iosif C, Måsbäck A. Fertility-sparing surgery and outcome in fertile women with ovarian borderline tumors and epithelial invasive ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 2007;134(1):110–4.

    Article  PubMed  Google Scholar 

  53. Kajiyama H, Shibata K, Mizuno M, et al. Long-term survival of young women receiving fertility-sparing surgery for ovarian cancer in comparison with those undergoing radical surgery. Br J Cancer. 2011;105(9):1288–94.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  54. Kajiyama H, Shibata K, Mizuno M, et al. Fertility-sparing surgery in patients with clear-cell carcinoma of the ovary: is it possible? Hum Reprod. 2011;26(12):3297–302.

    Article  PubMed  Google Scholar 

  55. Kajiyama H, Shibata K, Suzuki S, et al. Fertility-sparing surgery in young women with invasive epithelial ovarian cancer. Eur J Surg Oncol. 2010;36(4):404–8.

    Article  CAS  PubMed  Google Scholar 

  56. Bamias A, Psaltopoulou T, Sotiropoulou M, et al. Mucinous but not clear cell histology is associated with inferior survival in women with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy. Cancer. 2010;116(6):1462–8.

    Article  PubMed  Google Scholar 

  57. Park JY, Kim DY, Suh DS, et al. Outcomes of fertility-sparing surgery for invasive epithelial ovarian cancer: oncologic safety and reproductive outcomes. Gynecol Oncol. 2008;110(3):345–53.

    Article  PubMed  Google Scholar 

  58. Schilder JM, Thompson AM, DePriest PD, et al. Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. Gynecol Oncol. 2002;87(1):1–7.

    Article  PubMed  Google Scholar 

  59. Colombo N, Guthrie D, Chiari S, et al. International Collaborative Ovarian Neoplasm (ICON) collaborators. International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in patients with early-stage ovarian cancer. J Natl Cancer Inst. 2003;95(2):125–32.

    Article  PubMed  Google Scholar 

  60. Trimbos JB, Parmar M, Vergote I, et al. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst. 2003;95:105–12.

    Article  PubMed  Google Scholar 

  61. Winter-Roach BA, Kitchener HC, Dickinson HO. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database Syst Rev. 2012;3:CD004706.

    PubMed  Google Scholar 

  62. Collinson F, Qian W, Fossati R, Lissoni A, Williams C, Parmar M, Ledermann J, Colombo N, Swart AM. On behalf of the ICON1 collaborators. Optimal treatment of early-stage ovarian cancer (in press).

    Google Scholar 

  63. Vergote I, De Brabanter J, Fyles A, et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet. 2001;357:176–82.

    Article  CAS  PubMed  Google Scholar 

  64. Chan J, Fuh K, Shin J, et al. The treatment and outcomes of early-stage epithelial ovarian cancer: have we made any progress? Br J Cancer. 2008;98:1191–6.

    Article  PubMed Central  PubMed  Google Scholar 

  65. Chan JK, Tian C, Monk BJ, et al. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study. Cancer. 2008;112:2202–10.

    Article  PubMed  Google Scholar 

  66. Trope C, Kaern J, Hogberg T, et al. Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument. Ann Oncol. 2000;11:281–8.

    Article  CAS  PubMed  Google Scholar 

  67. Vergote IB, Kaern J, Abeler VM, et al. Analysis of prognostic factors in stage I epithelial ovarian carcinoma: importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse. Am J Obstet Gynecol. 1993;169:40–52.

    Article  CAS  PubMed  Google Scholar 

  68. Skirnisdottir I, Sorbe B, Karlsson M, et al. Prognostic importance of DNA ploidy and p53 in early stages of epithelial ovarian carcinoma. Int J Oncol. 2001;19:1295–302.

    CAS  PubMed  Google Scholar 

  69. Obermair A, Fuller A, Lopez-Varela E, et al. A new prognostic model for FIGO stage 1 epithelial ovarian cancer. Gynecol Oncol. 2007;104:607–11.

    Article  PubMed  Google Scholar 

  70. Moore RG, Brown AK, Miller MC, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2008;108:402–8.

    Article  CAS  PubMed  Google Scholar 

  71. Trimbos B, Timmers P, Pecorelli S, et al. Surgical staging and treatment of early ovarian cancer: long-term analysis from a randomized trial. J Natl Cancer Inst. 2010;102:982–7.

    Article  PubMed Central  PubMed  Google Scholar 

  72. Travis LB, Holowaty EJ, Bergfeldt K, et al. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med. 1999;340:351–7.

    Article  CAS  PubMed  Google Scholar 

  73. International Collaborative Ovarian Neoplasm Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet. 2002;360:505–15.

    Article  Google Scholar 

  74. Adams G, Zekri J, Wong H, et al. Platinum-based adjuvant chemotherapy for early-stage epithelial ovarian cancer: single or combination chemotherapy? BJOG. 2010;117:1459–67.

    Article  CAS  PubMed  Google Scholar 

  75. Metzger-Filho O, Moulin C, D’Hondt V. First-line systemic treatment of ovarian cancer: a critical review of available evidence and expectations for future directions. Curr Opin Oncol. 2010;22(5):513–20.

    Article  CAS  PubMed  Google Scholar 

  76. Elit L, Chambers A, Fyles A, et al. Systematic review of adjuvant care for women with stage I ovarian carcinoma. Cancer. 2004;101:1926–35.

    Article  PubMed  Google Scholar 

  77. Bell J, Brady MF, Young RC, et al. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2006;102:432–9.

    Article  CAS  PubMed  Google Scholar 

  78. Chan JK, Tian C, Fleming GF, et al. The potential benefit of 6 vs. 3 Cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study. Gynecol Oncol. 2010;116:301–6.

    Article  PubMed  Google Scholar 

  79. Mannel RS, Brady MF, Kohn EC, et al. A randomized phase III trial of IV carboplatin and paclitaxel 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 2011;122:89–94.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  80. Vergote IB, Vergote-De Vos LN, Abeler VM, et al. Randomized trial comparing cisplatin with radioactive phosphorus or whole-abdomen irradiation as adjuvant treatment of ovarian cancer. Cancer. 1992;69(3):741–9.

    Article  CAS  PubMed  Google Scholar 

  81. Bolis G, Colombo N, Pecorelli S, et al. Adjuvant treatment for early epithelial ovarian cancer: results of two randomized clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). GICOG: Gruppo Interregionale Collaborativo in Ginecologia Oncologica. Ann Oncol. 1995;6(9):887–93.

    CAS  PubMed  Google Scholar 

  82. du Bois A, Herrstedt J, Hardy-Bessard AC, et al. Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. J Clin Oncol. 2010;28(27):4162–9. doi:10.1200/JCO.2009.27.4696.

    Article  PubMed  Google Scholar 

  83. Bakkum-Gamez JN, Richardson DL, Seamon LG, et al. Is there a high-risk subgroup of stage I epithelial ovarian cancer that is most likely to benefit from 6 versus 3 cycles of adjuvant chemotherapy? Int J Gynecol Cancer. 2010;20(7):1125–31.

    Article  PubMed  Google Scholar 

  84. Katsumata N, Yasuda M, Takahashi F, et al., Japanese Gynecologic Oncology Group. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009;374(9698):1331–8.

    Google Scholar 

  85. Katsumata N, Yasuda M, Seiji Isonishi S, et al. Japanese Gynecologic Oncology Group. Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. J Clin Oncol. 2012;30: (suppl; abstr 5003).

    Google Scholar 

  86. Armstrong DK, Bundy B, Wenzel L, et al., Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34–43.

    Google Scholar 

  87. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473–83.

    Article  CAS  PubMed  Google Scholar 

  88. Trimbos JB. Staging of early ovarian cancer and the impact of lymph node sampling. Int J Gynecol Cancer. 2000;10(S1):8–11.

    Article  PubMed  Google Scholar 

  89. Sobin LH, Gospodarowicz M, Wittekind C. TNM classification of malignant tumours. 7th ed. Oxford: Union for International Cancer Control (UICC), Wiley-Blackwell; 2009.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gynaecological Oncology, West London Gynaecological Cancer Center and Ovarian Cancer Action Research Center, Imperial College London, Hammersmith Campus, Du Cane Road, London, W120NN, UK

    Christina Fotopoulou MD, PhD

  2. Norwich Clinical Trials Unit, Norwich Medical School, University of East Anglia, Norwich Research Park, Norwich, NR4 7TJ, UK

    Ann Marie Swart MBBS, MRCP, MSc

  3. Gynecologic Oncology and Reproductive Medicine, University of Texas, M.D. Anderson Cancer Center, 1155 Herman Pressler Dr, CPB 6.3271, Houston, TX, 77030, USA

    Robert L. Coleman MD

Authors
  1. Christina Fotopoulou MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ann Marie Swart MBBS, MRCP, MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert L. Coleman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christina Fotopoulou MD, PhD .

Editor information

Editors and Affiliations

  1. UCL Cancer Institute, University College London, London, United Kingdom

    Jonathan A. Ledermann

  2. Radiation Oncology, Leiden University Medical Center, Leiden, The Netherlands

    Carien L. Creutzberg

  3. Royal Women’s Hospital, The University of Melbourne, Melbourne, Australia

    Michael A. Quinn

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag London

About this chapter

Cite this chapter

Fotopoulou, C., Swart, A.M., Coleman, R.L. (2014). Controversies in the Treatment of Women with Early-Stage Epithelial Ovarian Cancer. In: Ledermann, J., Creutzberg, C., Quinn, M. (eds) Controversies in the Management of Gynecological Cancers. Springer, London. https://doi.org/10.1007/978-0-85729-910-9_1

Download citation

  • DOI: https://doi.org/10.1007/978-0-85729-910-9_1

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-0-85729-909-3

  • Online ISBN: 978-0-85729-910-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation